Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development

Cancer Research

Volumn 68, Issue 18, 2008, Pages 7638-7649

  Tran, Melissa A ^a   Gowda, Raghavendra ^a   Sharma, Arati ^a   Park, Eun Joo ^a   Adair, James ^a   Kester, Mark ^a   Smith, Nadine Barrie ^a   Robertson, Gavin P ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT3 PROTEIN; B RAF KINASE; ISOENZYME; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AKT3 PROTEIN, HUMAN; BRAF PROTEIN, HUMAN; NANOPARTICLE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; GENETICS; METHODOLOGY; MUTATION; NUDE MOUSE; SKIN TUMOR; TUMOR CELL LINE; ULTRASOUND THERAPY;

ANIMALS; CELL LINE, TUMOR; HUMANS; LIPOSOMES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NANOPARTICLES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SKIN NEOPLASMS; ULTRASONIC THERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54849373400     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6614     Document Type: Article

References (50)

1. Satyamoorthy K, Herlyn M. Cellular and molecular biology of human melanoma. Cancer Biol Ther 2002;1:14-7.
2. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
4. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003;121:1160-2.
5. Miller CJ, Cheung M, Sharma A, et al. Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 2004;123:990-2.
6. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64:7002-10.
7. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63:2881-90.
8. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005;65:2412-21.
9. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant (V600E) B-Raf cooperate to promote early melanoma development. Cancer Res 2008;68:3429-39.
10. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-202.
11. Brazas RM, Hagstrom JE. Delivery of small interfering RNA to mammalian cells in culture by using cationic lipid/polymer-based transfection reagents. Methods Enzymol 2005;392:112-24.
12. Gresch O, Engel FB, Nesic D, et al. New non-viral method for gene transfer into primary cells. Methods 2004;33:151-63.
13. Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 2004;558:63-8.
14. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007;8:173-84.
15. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005;107:222-39.
16. Zhang C, Tang N, Liu X, Liang W, Xu W, Torchilin VP. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 2006;112:229-39.
17. Halder J, Kamat AA, Landen CN, Jr., et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-24.
18. Pal A, Ahmad A, Khan S, et al. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol 2005;26:1087-91.
19. El Maghraby GM, Williams AC, Barry BW. Can drug-bearing liposomes penetrate intact skin? J Pharm Pharmacol 2006;58:415-29.
20. Lee SH, Jeong SK, Ahn SK. An update of the defensive barrier function of skin. Yonsei Med J 2006;47:293-306.
21. Ting WW, Vest CD, Sontheimer RD. Review of traditional and novel modalities that enhance the permeability of local therapeutics across the stratum corneum. Int J Dermatol 2004;43:538-47.
22. Lavon I, Kost J. Ultrasound and transdermal drug delivery. Drug Discov Today 2004;9:670-6.
23. Lee S, Newnham RE, Smith NB. Short ultrasound exposure times for noninvasive insulin delivery in rats using the lightweight cymbal array. IEEE Trans Ultrason Ferroelectr Freq Control 2004;51:176-80.
24. Park EJ, Werner J, Smith NB. Ultrasound mediated transdermal insulin delivery in pigs using a lightweight transducer. Pharm Res 2007;24:1396-401.
25. Smith NB, Lee S, Maione E, Roy RB, McElligott S, Shung KK. Ultrasound-mediated transdermal transport of insulin in vitro through human skin using novel transducer designs. Ultrasound Med Biol 2003;29:311-7.
26. Smith NB, Lee S, Shung KK. Ultrasound-mediated transdermal in vivo transport of insulin with low-profile cymbal arrays. Ultrasound Med Biol 2003;29:1205-10.
27. Satyamoorthy K, DeJesus E, Linnenbach AJ, et al. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 1997;7 Suppl 2:S35-42.
28. Stover T, Kester M. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther 2003;307:468-75.
29. Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005;11:3465-74.
30. Sharma A, Tran MA, Liang S, et al. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res 2006;66:8200-9.
31. Rasband WS. ImageJ. Bethesda (MD): U.S. National Institutes of Health; 1997-2007.
32. Meyers C. Organotypic (raft) epithelial tissue culture system for the differentiation-dependent replication of papillomavirus. Methods Cell Sci 1996;18:201-10.
33. Maione E, Shung KK, Meyer RJ, Jr., Hughes JW, Newnham RE, Smith NB. Transducer design for a portable ultrasound enhanced transdermal drug-delivery system. IEEE Trans Ultrason Ferroelectr Freq Control 2002;49:1430-6.
34. Newnham RE, Dogan A, inventors; Metal-electroactive ceramic composite transducer patent 5,729,077; 1998.
35. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
36. RNA interference - technical reference and application guide. Lafayette (CO): Dharmacon, Inc.; 2004.
37. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991;3:207-12.
38. Christensen C, Guldberg P. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF. Oncogene 2005;24:6292-302.
39. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007;17:117-27.
40. Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003;89:1620-6.
41. Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998;77:2336-42.
42. Bedogni B, O'Neill MS, Welford SM, et al. Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 2004;64:2552-60.
43. Bedogni B, Welford SM, Kwan AC, Ranger-Moore J, Saboda K, Powell MB. Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther 2006;5:3071-7.
44. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-44.
45. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther 2006;13:644-70.
46. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003;327:761-6.
47. Derfus AM, Chen AA, Min DH, Ruoslahti E, Bhatia SN. Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem 2007;18:1391-6.
48. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.
49. Treat J, Damjanov N, Huang C, Zrada S, Rahman A. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Huntingt) 2001;15:44-8.
50. Balch CM. Cutaneous melanoma. 3rd ed. St. Louis (MO): Quality Medical Pub.; 1998.